William Blair analyst Myles Minter has reiterated their neutral stance on ALEC stock, giving a Hold rating yesterday.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Myles Minter has given his Hold rating due to a combination of factors surrounding Alector’s recent clinical performance and future platform potential. Multiple late-stage trials, including programs for Alzheimer’s disease and frontotemporal dementia, failed to meet key efficacy thresholds, prompting termination of those studies and signaling a near-term reset of the company’s pipeline.
At the same time, he sees a rationale to remain neutral rather than outright negative because the next wave of candidates built on Alector’s BBB-penetrant Antibody Brain Carrier platform could address prior delivery limitations and support future upside. Promising preclinical siRNA assets and the planned entry of an anti-Abeta program into the clinic in 2027, combined with an upcoming external proof-of-concept readout for tau-targeting approaches, create optionality, but the absence of near-term in-human data keeps him on the sidelines with a Market Perform stance.
Minter covers the Healthcare sector, focusing on stocks such as Dianthus Therapeutics, Moderna, and Axsome Therapeutics. According to TipRanks, Minter has an average return of 38.2% and a 62.40% success rate on recommended stocks.